International Clinical Trial: Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer

Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122486) titled 'Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer' on April 14.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Fudan University Shanghai Cancer Center

Condition: Triple-negative breast cancer

Intervention: Trial Group:Ivosidenib (AK112) 20 mg/kg intravenous infusion every two weeks for 12 doses (neoadjuvant phase) combined with chemotherapy: nab-paclitaxel (100 mg/m^2 once weekly) and carboplatin (AUC 1.5 once weekly) for 4 cycles, followed by epirubicin (90 mg/m^2) combined with cyclophosphamide (500 mg/m^2) for 4 doses surgery ...